We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Advisers Recommend Approval of Vanda’s Sleep Drug for the Blind
FDA Advisers Recommend Approval of Vanda’s Sleep Drug for the Blind
FDA advisers overwhelmingly voted Nov. 14 to recommend approval of Vanda’s sleep drug tasimelteon for the visually impaired despite some concern over a clinical trial’s primary endpoint.